54143-55-4
54143-55-4
Chemical Structure
Flecainide
- CAS No.: 54143-55-4
- Formula:C17H20F6N2O3
- Molecular Weight:414.34
IUPAC Name: N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide
InChIKey: DJBNUMBKLMJRSA-UHFFFAOYSA-N
SMILES: O=C(C1=CC(OCC(F)(F)F)=CC=C1OCC(F)(F)F)NCC2NCCCC2
Biological Activity: Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Flecainide | 99.98% | Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Flecainide (Standard) | ≥98% | Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Flecainide-d3 | 99.9% | Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kuroda Y, et al. Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes. Biochem Biophys Rep. 2017 Jan 11;9:245-256. [Content Brief]
- [2]. Watanabe H, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 Apr;15(4):380-3. [Content Brief]
